Horizon Discovery has signed a research service collaboration with Boehringer Ingelheim to support BI’s oncology programs using its Discovery Toolbox for research projects and profiling of compounds from hit-to-lead to preclinical stages. Financial terms were not disclosed.
Horizon will evaluate compounds across a broad panel of X-MAN isogenic models and selected 2D/3D phenotypic assays, and will provide an FTE and access to its custom cell line generation services to support the programs. Horizon will also apply its genome editing technology GENESIS to develop human isogenic disease model cell lines according to Boehringer’s specifications.
Kam Dhaliwal, vice president of sales, Horizon, said “We are delighted that Boehringer Ingelheim has selected Horizon as a partner for its drug discovery programs, in recognition of the value our X-MAN cell lines and drug discovery services can add to the search for novel treatments for cancer."
Horizon Discovery, Boehringer in Research Alliance
Published January 14, 2013
blog comments powered by Disqus